Literature DB >> 22204340

Approaches targeting K(V)10.1 open a novel window for cancer diagnosis and therapy.

L A Pardo1, D Gómez-Varela, F Major, K Sansuk, R Leurs, B R Downie, L F Tietze, W Stühmer.   

Abstract

K(V)10.1 has recently become generally accepted as a promising cancer target, as it is ectopically expressed in the majority of solid tumors. Due to its cell-surface accessibility, K(V)10.1 has a strong potential for tumor treatment and diagnosis. Given that its mode of action is likely independent of conventional cancer pathways such as tyrosine kinases, K(V)10.1 opens a novel window for treating cancer. In this review we will give an overview of the current status of data linking K(V)10.1 to cancer, and propose techniques that could exploit K(V)10.1's properties for the management of cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22204340     DOI: 10.2174/092986712798992011

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  12 in total

1.  Voltage-dependent K+ channels as oncotargets in malignant gliomas.

Authors:  Florence Lefranc; Henri-Benjamin Pouleau; Michal Rynkowski; Olivier De Witte
Journal:  Oncotarget       Date:  2012-05

2.  Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase.

Authors:  Laetitia Moreno Y Banuls; Adriana Katz; Walter Miklos; Alessio Cimmino; Daniel M Tal; Elena Ainbinder; Martin Zehl; Ernst Urban; Antonio Evidente; Brigitte Kopp; Walter Berger; Olivier Feron; Steven Karlish; Robert Kiss
Journal:  Mol Cancer       Date:  2013-04-26       Impact factor: 27.401

Review 3.  Cell volume regulation in epithelial physiology and cancer.

Authors:  Stine F Pedersen; Else K Hoffmann; Ivana Novak
Journal:  Front Physiol       Date:  2013-08-30       Impact factor: 4.566

4.  Synthesis of novel purpurealidin analogs and evaluation of their effect on the cancer-relevant potassium channel KV10.1.

Authors:  Lien Moreels; Chinmay Bhat; Manuela Voráčová; Steve Peigneur; Hannah Goovaerts; Eero Mäki-Lohiluoma; Farrah Zahed; Luis A Pardo; Jari Yli-Kauhaluoma; Paula Kiuru; Jan Tytgat
Journal:  PLoS One       Date:  2017-12-08       Impact factor: 3.240

5.  Prominent role of RAB39A-RXRB axis in cancer development and stemness.

Authors:  Tokuhiro Chano; Hiroko Kita; Sofia Avnet; Silvia Lemma; Nicola Baldini
Journal:  Oncotarget       Date:  2018-01-04

6.  Antidepressant drug use in glioblastoma patients: an epidemiological view.

Authors:  Dorothee Gramatzki; James Louis Rogers; Marian Christoph Neidert; Caroline Hertler; Emilie Le Rhun; Patrick Roth; Michael Weller
Journal:  Neurooncol Pract       Date:  2020-04-25

7.  Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival.

Authors:  Ramón Martínez; Walter Stühmer; Sabine Martin; Julian Schell; Andrea Reichmann; Veit Rohde; Luis Pardo
Journal:  BMC Cancer       Date:  2015-11-03       Impact factor: 4.430

Review 8.  Molecular basis of potassium channels in pancreatic duct epithelial cells.

Authors:  Mikio Hayashi; Ivana Novak
Journal:  Channels (Austin)       Date:  2013-08-20       Impact factor: 2.581

9.  In vivo imaging of tumour xenografts with an antibody targeting the potassium channel Kv10.1.

Authors:  Joanna Napp; Luis A Pardo; Franziska Hartung; Lutz F Tietze; Walter Stühmer; Frauke Alves
Journal:  Eur Biophys J       Date:  2016-07-21       Impact factor: 1.733

10.  APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1.

Authors:  Lien Moreels; Steve Peigneur; Diogo T Galan; Edwin De Pauw; Lászlo Béress; Etienne Waelkens; Luis A Pardo; Loïc Quinton; Jan Tytgat
Journal:  Mar Drugs       Date:  2017-09-13       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.